Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.
Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.